Your browser is no longer supported. Please, upgrade your browser.
Settings
CYCC Cyclacel Pharmaceuticals, Inc. daily Stock Chart
CYCC [NASD]
Cyclacel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.63 Insider Own18.62% Shs Outstand12.66M Perf Week-3.66%
Market Cap10.00M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float10.17M Perf Month-1.24%
Income-7.50M PEG- EPS next Q-0.17 Inst Own6.30% Short Float1.48% Perf Quarter-34.17%
Sales- P/S- EPS this Y44.40% Inst Trans12.56% Short Ratio1.55 Perf Half Y-49.36%
Book/sh1.38 P/B0.57 EPS next Y-9.50% ROA-31.90% Target Price7.00 Perf Year-50.93%
Cash/sh1.50 P/C0.53 EPS next 5Y- ROE-38.80% 52W Range0.51 - 1.87 Perf YTD30.58%
Dividend- P/FCF- EPS past 5Y37.80% ROI- 52W High-57.75% Beta3.48
Dividend %- Quick Ratio5.20 Sales past 5Y- Gross Margin- 52W Low54.90% ATR0.06
Employees12 Current Ratio5.20 Sales Q/Q- Oper. Margin- RSI (14)49.85 Volatility5.69% 7.45%
OptionableNo Debt/Eq0.00 EPS Q/Q80.50% Profit Margin- Rel Volume0.28 Prev Close0.80
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout- Avg Volume97.60K Price0.79
Recom- SMA20-0.24% SMA504.79% SMA200-36.26% Volume27,411 Change-1.50%
Sep-07-18Initiated Ladenburg Thalmann Buy
Oct-16-15Initiated H.C. Wainwright Buy $5
Feb-04-10Initiated Roth Capital Buy $7
Oct-28-09Initiated Merriman Buy
Aug-12-08Initiated Piper Jaffray Buy $5
Mar-12-08Reiterated Needham & Co Buy $12 → $7
Mar-12-08Reiterated Collins Stewart Buy $12 → $13
Mar-12-08Reiterated Cantor Fitzgerald Buy $10.50 → $9
Nov-27-07Reiterated Cantor Fitzgerald Buy $14 → $10.50
Aug-10-07Reiterated Cantor Fitzgerald Buy $12 → $14
Jun-04-07Reiterated Needham & Co Buy $9 → $12
Apr-23-07Initiated Lazard Capital Buy $11
Apr-10-07Initiated Cantor Fitzgerald Buy $12
Feb-05-19 07:00AM  Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference GlobeNewswire
Jan-24-19 07:25AM  New Research: Key Drivers of Growth for Square, American International Group, PolyOne, Sonoco Products, Enviva Partners, LP, and Cyclacel Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-07-19 07:00AM  Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 GlobeNewswire
Jan-03-19 11:11PM  Edited Transcript of CYCC earnings conference call or presentation 12-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-27-18 07:00AM  Cyclacel Pharmaceuticals to Present at Biotech Showcase 2019 in San Francisco GlobeNewswire
Dec-25-18 02:25PM  Does Cyclacel Pharmaceuticals, Inc.s (NASDAQ:CYCC) CEO Pay Reflect Performance? Simply Wall St.
Dec-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-13-18 07:54AM  The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut Benzinga
Nov-12-18 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-06-18 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results GlobeNewswire
Oct-25-18 08:30AM  Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-23-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference GlobeNewswire
Oct-04-18 07:00AM  Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies GlobeNewswire +6.60%
Sep-26-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-20-18 01:01PM  What does Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Balance Sheet Tell Us About Its Future? Simply Wall St.
Sep-12-18 07:00AM  Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors GlobeNewswire -5.56%
Sep-10-18 07:00AM  Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer GlobeNewswire
Sep-05-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group New Research Emphasizes Economic Growth GlobeNewswire -5.73%
Aug-29-18 07:00AM  Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-27-18 09:45PM  Edited Transcript of CYCC earnings conference call or presentation 9-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-16-18 08:15AM  Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource Discovering Underlying Factors of Influence GlobeNewswire
Aug-09-18 04:05PM  Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results GlobeNewswire
May-25-18 02:09PM  Who Really Owns Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)? Simply Wall St.
May-21-18 05:23PM  Edited Transcript of CYCC earnings conference call or presentation 14-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-14-18 04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire
12:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:51AM  Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Earnings Dropped -23.81%, Did Its Industry Show Weakness Too? Simply Wall St.
May-08-18 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results GlobeNewswire
May-04-18 08:10AM  Recent Analysis Shows Lancaster Colony, Calavo Growers, Acuity Brands, Cyclacel Pharmaceuticals, Enbridge Energy Management, and Nasdaq Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-17-18 09:00AM  Cyclacels CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia GlobeNewswire -5.23%
Apr-16-18 07:00AM  Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting GlobeNewswire -8.28%
Apr-13-18 11:38AM  The Week Ahead In Biotech: PDUFA Dates, IPOs And More Benzinga
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE
Mar-29-18 01:16PM  Edited Transcript of CYCC earnings conference call or presentation 28-Mar-18 8:30pm GMT Thomson Reuters StreetEvents
Mar-28-18 04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
12:30PM  Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-20-18 07:45AM  Consolidated Research: 2018 Summary Expectations for Triangle Capital, Federal Agricultural Mortgage, Cyclacel Pharmaceuticals, Sterling Construction, Select Energy Services, and Citi Trends Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-15-18 07:00AM  Phase 1 Clinical Data With Cyclacels CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting GlobeNewswire
Mar-06-18 07:19AM  Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference GlobeNewswire
Feb-21-18 07:00AM  Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations GlobeNewswire
Feb-06-18 07:00AM  Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire
Feb-05-18 06:29PM  Should You Be Concerned About Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Shareholders? Simply Wall St.
Jan-24-18 07:00AM  Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference GlobeNewswire
Jan-19-18 07:55PM  Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Earnings Declined -24.93%, But How Did It Fare Against The Industry? Simply Wall St.
Jan-18-18 08:20AM  New Research Coverage Highlights Cyclacel Pharmaceuticals, American Assets Trust, Roper Technologies, Central Garden & Pet, Home, and Tompkins Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-09-18 07:00AM  Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 GlobeNewswire
Jan-02-18 01:09PM  What You Must Know About Cyclacel Pharmaceuticals Incs (NASDAQ:CYCC) Financial Health Simply Wall St.
Dec-13-17 01:06PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : December 13, 2017 Capital Cube
Dec-12-17 07:00AM  Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting GlobeNewswire -9.98%
Nov-27-17 01:02PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
Nov-22-17 02:05AM  Edited Transcript of CYCC earnings conference call or presentation 9-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-09-17 04:05PM  Cyclacel Pharmaceuticals Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 07:00AM  Cyclacel Pharmaceuticals to Release Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:02AM  Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting GlobeNewswire
Oct-16-17 10:49AM  The Week Ahead: Earnings, Earnings, And More Earnings Benzinga
Sep-21-17 07:00AM  Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire +21.41%
Sep-13-17 08:00AM  Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals and MannKind Corporation ACCESSWIRE
Sep-08-17 07:00AM  Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-16-17 08:11PM  Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
07:20AM  Featured Company News - Soligenix Receives $2.5 million in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine ACCESSWIRE
Aug-09-17 04:05PM  Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results GlobeNewswire
12:00PM  Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 07:00AM  Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression GlobeNewswire
Aug-02-17 07:00AM  Cyclacel Pharmaceuticals to Release Second Quarter 2017 Financial Results GlobeNewswire
Jul-21-17 02:00PM  Cyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option GlobeNewswire +11.70%
Jul-20-17 08:10AM  Today's Research Reports on Trending Tickers: Cyclacel Pharmaceuticals Inc. and Canadian Solar Inc. Accesswire
May-19-17 11:05AM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
May-11-17 07:16PM  Edited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT Thomson Reuters StreetEvents
04:05PM  Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results GlobeNewswire
12:00PM  Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call Accesswire
May-05-17 07:00AM  Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results GlobeNewswire
Apr-11-17 09:59AM  Company News for April 11, 2017 Zacks
Apr-07-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Brainstorm Cell Therapeutics and Cyclacel Pharmaceuticals Accesswire
Apr-05-17 04:37PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : April 5, 2017 Capital Cube -18.24%
Apr-04-17 04:40PM  Rising Biotechs: Paratek Among Stocks Surging On Trial Results Investor's Business Daily +27.26%
01:00PM  Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140 GlobeNewswire
12:24PM  Adam Feuerstein Unloads On Cyclacel Pharmaceuticals, Will Break Down Its Manipulation On PreMarket Prep Benzinga
09:15AM  Novocure and Cyclacel Pharmaceuticals Surge on Positive FDA Trial News Accesswire
09:01AM  Cyclacel Pharmaceuticals, Inc. :CYCC-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017 Capital Cube
Apr-03-17 11:32AM  Cyclacel's CYC065 Succeeds in Lung Cancer Study Investopedia +74.46%
Apr-02-17 01:00PM  Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways GlobeNewswire
Mar-28-17 07:36PM  Edited Transcript of CYCC earnings conference call or presentation 28-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
04:16PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
04:05PM  Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close
Mar-21-17 07:00AM  Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-13-17 04:31PM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events +7.09%
Mar-07-17 07:00AM  Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI GlobeNewswire +9.07%
Feb-24-17 01:35PM  Heres What Happened With Cyclacel Pharmaceuticals Inc (CYCC) And Nivalis Therapeutics Inc (NVLS) at Insider Monkey
09:23AM  Cyclacel Tanks on Leukemia Drug Failure at Investopedia
Feb-23-17 09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results -25.14%
08:17AM  CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:50AM  Cyclacel's stock plunges after disappointing trial results of its cancer treatment at MarketWatch
07:19AM  Cyclacel's leukemia drug for elderly patients fails in key study
06:57AM  Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia GlobeNewswire
Feb-06-17 07:00AM  Cyclacel Pharmaceuticals to Present at the 19th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-19-17 12:47PM  ETFs with exposure to Cyclacel Pharmaceuticals, Inc. : January 19, 2017
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.